<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01789229</url>
  </required_header>
  <id_info>
    <org_study_id>EK 260/2003</org_study_id>
    <nct_id>NCT01789229</nct_id>
  </id_info>
  <brief_title>Tumor Bank for Tissue Samples</brief_title>
  <official_title>Establishment of a Tissue Sample Bank in the Field of Gynaecological Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Establishment of a tumor bank, consisting of tissue samples of tumor patients (benign and
      malign tumors) and healthy people as controls. The tissue samples will be collected
      systematically together with the corresponding clinical data. The biological samples, the
      clinical date together with prospective experimental date constitute the entity of the tissue
      tumor bank.

      This tumor bank for tissue samples, together with our tumorbank for blood samples
      (NCT01763125) combined constitute the entity &quot;Tumorbank&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to
      translational research. The relevance of &quot;translational oncology&quot; will only increase in the
      future -&quot;From bench to bedside&quot; - the swift implementation of new science research results in
      clinical studies in order to expedite progress in clinical cancer therapy for the benefit of
      the patient.

      Its almost a matter of course in the medical science today to collect biological samples
      together with clinical information thereby creating the foundation for future excellent
      fundamental research.

      The aim of this tumor bank is to consist of biological samples (together with a blood bank -
      see NCT01763125) and isolates of tumor patients and healthy people as controls. The
      biological samples, the clinical date together with prospective experimental date constitute
      the entity of the tumor bank. The content of the tumor bank can provide essential material
      for current and future research (e.g. analyses of prognostic or predictive tumor markers;
      genetically analysis (polymorphism, mutation, hypermethylation; verification and
      characterisation of disseminated tumor cells).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2003</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.</measure>
    <time_frame>14 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Neoplasms of the Female Genitalia</condition>
  <condition>Lung Neoplasms</condition>
  <condition>Endocrine Gland Neoplasms</condition>
  <arm_group>
    <arm_group_label>Malignant tumors</arm_group_label>
    <description>Patients who have one of the Neoplasms stated above under &quot;conditions&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign controls</arm_group_label>
    <description>Patients with a benign tumor or an inflammatory disease - to be matched by age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor tissue collection</intervention_name>
    <description>Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.
Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.
Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger.</description>
    <arm_group_label>Malignant tumors</arm_group_label>
    <arm_group_label>Benign controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sampling of ascites and pleural effusion</intervention_name>
    <description>Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.</description>
    <arm_group_label>Malignant tumors</arm_group_label>
    <arm_group_label>Benign controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collecting urine samples</intervention_name>
    <description>Patient is asked to give a urine sample. Urine is collected in urine beaker.</description>
    <arm_group_label>Malignant tumors</arm_group_label>
    <arm_group_label>Benign controls</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collecting saliva sample</intervention_name>
    <description>Saliva sample is collected by spatula from the mouth cavity of the patient.</description>
    <arm_group_label>Malignant tumors</arm_group_label>
    <arm_group_label>Benign controls</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collecting sputum</intervention_name>
    <description>Patient is asked to produce sputum into a 50ml lab tube.</description>
    <arm_group_label>Malignant tumors</arm_group_label>
    <arm_group_label>Benign controls</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collecting stool samples</intervention_name>
    <description>Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.</description>
    <arm_group_label>Malignant tumors</arm_group_label>
    <arm_group_label>Benign controls</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lavage/Irrigation</intervention_name>
    <description>Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.</description>
    <arm_group_label>Malignant tumors</arm_group_label>
    <arm_group_label>Benign controls</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Universal tumor bank
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients/people. Minimum age 18 years Characteristics: Recruited at the
        Medical University Vienna or at one of the facilities cooperating with the Vienna Med.
        University
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Female

          -  Age 18 to 90 years max.

          -  Just one current known malignant disease or just one current inflammatory disease

        Exclusion Criteria:

          -  Inflammatory disease and malignant disease

          -  multiple malignancies

          -  multiple diseases

          -  underage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeillinger, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Dptm. of Obstetrics &amp; Gynaecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Zeillinger, Prof.Dr.</last_name>
    <phone>+43140400</phone>
    <phone_ext>7831</phone_ext>
    <email>robert.zeillinger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina M Pecha</last_name>
    <phone>+4340400</phone>
    <phone_ext>2784</phone_ext>
    <email>nina.pecha@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven - Department of Obstetrics and Gynaecology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace Vergote, Prof.Dr.</last_name>
      <phone>+32/1634</phone>
      <phone_ext>4208</phone_ext>
      <email>ignace.vergote@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Joke de Roover</last_name>
      <phone>+32 16 34</phone>
      <phone_ext>74 19</phone_ext>
      <email>joke.deroover@uz.kuleuven.ac.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité University - Campus Virchow Chlinic</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalid Sehouli, Prof.Dr.</last_name>
      <email>Jalid.Sehouli@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Ioana Braicu, Dr.</last_name>
      <phone>+49 30 450 564</phone>
      <phone_ext>002</phone_ext>
      <email>ioana@braicu.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Hofstetter G, Berger A, Fiegl H, Slade N, Zorić A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, Marth C, Zeimet AG, Concin N, Zeillinger R. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene. 2010 Apr 1;29(13):1997-2004. doi: 10.1038/onc.2009.482. Epub 2010 Jan 18.</citation>
    <PMID>20101229</PMID>
  </results_reference>
  <results_reference>
    <citation>Tong D, Heinze G, Pils D, Wolf A, Singer CF, Concin N, Hofstetter G, Schiebel I, Rudas M, Zeillinger R. Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients. BMC Cancer. 2010 Dec 15;10:682. doi: 10.1186/1471-2407-10-682.</citation>
    <PMID>21159173</PMID>
  </results_reference>
  <results_reference>
    <citation>Grimm C, Watrowski R, Baumühlner K, Natter C, Tong D, Wolf A, Zeillinger R, Leodolter S, Reinthaller A, Hefler L. Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol. 2011 Jun 1;121(3):537-41. doi: 10.1016/j.ygyno.2011.02.019. Epub 2011 Mar 3.</citation>
    <PMID>21376376</PMID>
  </results_reference>
  <results_reference>
    <citation>Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer. 2011 Nov 8;105(10):1593-9. doi: 10.1038/bjc.2011.433. Epub 2011 Oct 18.</citation>
    <PMID>22009029</PMID>
  </results_reference>
  <results_reference>
    <citation>Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M. Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Cancer. 2013 Mar 1;119(5):946-54. doi: 10.1002/cncr.27850. Epub 2012 Oct 23.</citation>
    <PMID>23096450</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2013</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Univ.Prof.Dr. Robert Zeillinger</investigator_full_name>
    <investigator_title>Univ.Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Endometrium carcinoma</keyword>
  <keyword>Cervix carcinoma,</keyword>
  <keyword>Mamma carcinoma,</keyword>
  <keyword>Prostata carcinoma</keyword>
  <keyword>Colon carcinoma</keyword>
  <keyword>Rectal carcinoma</keyword>
  <keyword>Bronchus carcinoma</keyword>
  <keyword>NSCLC (non small cell lung cancer) &amp; SCLC (small cell lung cancer)</keyword>
  <keyword>Prostate carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

